Medical Microinstruments, Inc. (MMI), a robotics company focused on complex conditions, announced on October 8, 2026, that it has closed a US$125 million Series D financing round. The investment was led by existing investor BioStar Capital, with participation from S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor. The company said the capital will support commercial expansion and clinical evidence development for its Symani Surgical System.
Commercial Growth and Market Adoption
MMI reported approximately 50 installed Symani systems and around 3,500 complex microsurgical procedures performed worldwide. The financing will support continued commercial expansion in the United States and key global markets while strengthening the foundation needed to expand patient access. The company is working with innovation-driven hospitals to develop robotic microsurgery programs that bring the Symani platform to more surgeons and patients.
Demand and Scaling Strategy
Demand for robotic microsurgery has been demonstrated at leading institutions around the world. Mark Toland, CEO of MMI, said the company has proven that demand and is now focused on translating adoption into scale. The new investment gives MMI the ability to expand its reach, accelerate adoption, and continue advancing the platform.
New Funding and Investor Backing
The Series D round was led by BioStar Capital, an existing investor, and was described as oversubscribed. New investors included S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor. Existing investors also contributed to the round, reflecting strong conviction in MMI's opportunity for continued growth and the expanding global adoption of robotic microsurgery.
Investor Perspective on Transformational Potential
Dr. Louie Cannon, founder and senior managing director of BioStar Capital, said MMI represents a transformational medical technology with the potential to revolutionize patient care. He noted that the most consequential innovations create capabilities that medicine did not have before. BioStar views MMI's work in cancer-related lymphedema as evidence of that potential, with more opportunities expected as scientific understanding of the lymphatic system advances.
Clinical Evidence and Technology Advancement
MMI will invest in clinical trials and outcomes data, including the REMIND study, to expand the applications for Symani and support broader adoption. Toland said the greatest potential for the technology may ultimately lie in areas that are only beginning to be investigated. Through research such as the REMIND study for Alzheimer's disease, MMI is building evidence and clinical experience that could help define where robotic microsurgery goes next.
Platform Innovation and Founding Mission
The company is also advancing the platform through innovation in areas such as energy instruments and digital surgery capabilities. These efforts are intended to broaden the range of procedures that robotic microsurgery can address. MMI was founded to transform open surgery by extending the capabilities of surgeons at the microsurgical level.
Addressing Complex Patient Needs
Robotic microsurgery programs are being developed with hospitals to address delicate cancer and trauma-related reconstructive surgery, as well as lymphatic and nerve repair options that improve quality of life. MMI is working to bring the capabilities of Symani to more surgeons and patients in need of these procedures. Cancer-related lymphedema is one area where MMI is already demonstrating new capabilities, with continued research expected to reveal further opportunities.
The Series D financing positions MMI to move beyond early adoption and build scale in robotic microsurgery. With a growing installed base, expanding clinical evidence, and support from both existing and new investors, the company is pursuing broader patient access in delicate reconstructive and repair procedures. MMI's continued research and commercial momentum signal a meaningful step forward for the field.